Last 12 months
Inside the activity.
0 purchase rows · 37 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 12 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2025 Filed Mar 19, 2025 20:01 UTC |
Waddill William D.Director
|
SaleCommon Stock | 4,000 | $54.25 | $217,000.00 |
DisclosureSEC source: 0001104659-25-025535 · tm259742-1_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,130 F1 · kind: Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 22:21 UTC |
MOLINA ARTURO MDChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,077 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-024063 · tm259281-2_4seq1.xml · derivative · entry 5 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,785 Underlying: Common Stock · 2,077 shares Expires 2035-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 22:21 UTC |
MOLINA ARTURO MDChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 28,437 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001104659-25-024063 · tm259281-2_4seq1.xml · derivative · entry 4 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,063 Underlying: Common Stock · 28,437 shares Expires 2034-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 22:21 UTC |
MOLINA ARTURO MDChief Medical Officer
|
SaleCommon Stock | 30,514 | $55.74 | $1,700,850.36 |
DisclosureSEC source: 0001104659-25-024063 · tm259281-2_4seq1.xml · nonDerivative · entry 3 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,892 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.245 to $56.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 22:21 UTC |
MOLINA ARTURO MDChief Medical Officer
|
Exercise / conversionCommon Stock | 2,077 | $38.98 | $80,961.46 |
DisclosureSEC source: 0001104659-25-024063 · tm259281-2_4seq1.xml · nonDerivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,406 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 22:21 UTC |
MOLINA ARTURO MDChief Medical Officer
|
Exercise / conversionCommon Stock | 28,437 | $23.42 | $665,994.54 |
DisclosureSEC source: 0001104659-25-024063 · tm259281-2_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,329 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 22:20 UTC |
Ali AsifChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 9,700 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001104659-25-024062 · tm259281-1_4seq1.xml · derivative · entry 5 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,800 Underlying: Common Stock · 9,700 shares Expires 2032-04-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option was granted to the Reporting Person on April 18, 2022, one quarter vested on April 18, 2023 and the remaining three quarters vest in equal monthly installments through April 18, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 22:20 UTC |
Ali AsifChief Financial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,203 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-25-024062 · tm259281-1_4seq1.xml · derivative · entry 4 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,547 Underlying: Common Stock · 15,203 shares Expires 2033-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option was granted to the Reporting Person on January 16, 2023 and vests in 48 equal monthly installments following the date of grant, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 22:20 UTC |
Ali AsifChief Financial Officer
|
SaleCommon Stock | 24,903 | $58.73 | $1,462,553.19 |
DisclosureSEC source: 0001104659-25-024062 · tm259281-1_4seq1.xml · nonDerivative · entry 3 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,821 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.12 to $59.235. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 22:20 UTC |
Ali AsifChief Financial Officer
|
Exercise / conversionCommon Stock | 9,700 | $19.19 | $186,143.00 |
DisclosureSEC source: 0001104659-25-024062 · tm259281-1_4seq1.xml · nonDerivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 22:20 UTC |
Ali AsifChief Financial Officer
|
Exercise / conversionCommon Stock | 15,203 | $12.17 | $185,020.51 |
DisclosureSEC source: 0001104659-25-024062 · tm259281-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 01:02 UTC |
PATEL DINESH V PH DDirector · President and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001104659-25-021045 · tm258430-1_4seq1.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 24,000 shares Expires 2026-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These stock options are fully vested. Read SEC document |
| March 05, 2025 Filed Mar 6, 2025 01:02 UTC |
PATEL DINESH V PH DDirector · President and CEO
|
Exercise / conversionCommon Stock | 24,000 | $4.21 | $101,040.00 |
DisclosureSEC source: 0001104659-25-021045 · tm258430-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 564,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 19, 2025 Filed Feb 20, 2025 22:25 UTC |
PATEL DINESH V PH DDirector · President and CEO
|
SaleCommon Stock | 5,359 | $38.18 | $204,606.62 |
DisclosureSEC source: 0001104659-25-015734 · tm257231-1_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 540,260 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 16, 2025 Filed Jan 17, 2025 22:45 UTC |
Ali AsifChief Financial Officer
|
SaleCommon Stock | 2,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004569 · tm253633-1_4seq1.xml · nonDerivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,821 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 16, 2025 Filed Jan 17, 2025 22:45 UTC |
Ali AsifChief Financial Officer
|
SaleCommon Stock | 1,317 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004569 · tm253633-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,422 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 16, 2025 Filed Jan 17, 2025 22:47 UTC |
MOLINA ARTURO MDChief Medical Officer
|
SaleCommon Stock | 3,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004571 · tm253633-3_4seq1.xml · nonDerivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,892 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 16, 2025 Filed Jan 17, 2025 22:47 UTC |
MOLINA ARTURO MDChief Medical Officer
|
SaleCommon Stock | 388 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004571 · tm253633-3_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,144 F1 · shares: Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 22:46 UTC |
PATEL DINESH V PH DDirector · President and CEO
|
Tax withholdingCommon Stock | 12,636 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004570 · tm253633-2_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 545,619 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:07 UTC |
PATEL DINESH V PH DDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 181,472 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001429 · tm252003-4_4seq1.xml · derivative · entry 2 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,472 Underlying: Common Stock · 181,472 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:07 UTC |
PATEL DINESH V PH DDirector · President and CEO
|
GrantCommon Stock | 149,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001429 · tm252003-4_4seq1.xml · nonDerivative · entry 1 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 558,255 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:05 UTC |
Ali AsifChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 38,520 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001426 · tm252003-1_4seq1.xml · derivative · entry 2 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,520 Underlying: Common Stock · 38,520 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:05 UTC |
Ali AsifChief Financial Officer
|
GrantCommon Stock | 31,779 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001426 · tm252003-1_4seq1.xml · nonDerivative · entry 1 Ali Asif · CIK 0001921163 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,739 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 18:10 UTC |
O'Dowd Sarah ADirector
|
GrantStock Option (right to buy) · Derivative | 6,584 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001434 · tm252003-7_4seq1.xml · derivative · entry 2 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,584 Underlying: Common Stock · 6,584 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 18:10 UTC |
O'Dowd Sarah ADirector
|
GrantCommon Stock | 5,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001434 · tm252003-7_4seq1.xml · nonDerivative · entry 1 O'Dowd Sarah A · CIK 0001447149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,130 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:11 UTC |
Waddill William D.Director
|
GrantStock Option (right to buy) · Derivative | 6,584 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001435 · tm252003-8_4seq1.xml · derivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,584 Underlying: Common Stock · 6,584 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:11 UTC |
Waddill William D.Director
|
GrantCommon Stock | 5,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001435 · tm252003-8_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,130 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:09 UTC |
Williams Lewis TDirector
|
GrantStock Option (right to buy) · Derivative | 6,584 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001432 · tm252003-6_4seq1.xml · derivative · entry 2 Williams Lewis T · CIK 0001475714 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,584 Underlying: Common Stock · 6,584 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:09 UTC |
Williams Lewis TDirector
|
GrantCommon Stock | 5,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001432 · tm252003-6_4seq1.xml · nonDerivative · entry 1 Williams Lewis T · CIK 0001475714 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,130 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:08 UTC |
SELICK HAROLD EDirector
|
GrantStock Option (right to buy) · Derivative | 6,584 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001430 · tm252003-5_4seq1.xml · derivative · entry 2 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,584 Underlying: Common Stock · 6,584 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:08 UTC |
SELICK HAROLD EDirector
|
GrantCommon Stock | 5,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001430 · tm252003-5_4seq1.xml · nonDerivative · entry 1 SELICK HAROLD E · CIK 0001287233 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,126 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:07 UTC |
Giraudo BryanDirector
|
GrantStock Option (right to buy) · Derivative | 6,584 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001428 · tm252003-3_4seq1.xml · derivative · entry 3 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,584 Underlying: Common Stock · 6,584 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:07 UTC |
Giraudo BryanDirector
|
GrantCommon Stock | 5,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001428 · tm252003-3_4seq1.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,130 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in full on January 15, 2026, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:06 UTC |
MOLINA ARTURO MDChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 49,862 | $0.00 Strike: $38.98 | $0.00 |
DisclosureSEC source: 0001104659-25-001427 · tm252003-2_4seq1.xml · derivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,862 Underlying: Common Stock · 49,862 shares Expires 2035-01-02 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following January 2, 2025, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 23:06 UTC |
MOLINA ARTURO MDChief Medical Officer
|
GrantCommon Stock | 41,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-001427 · tm252003-2_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,532 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will vest in four equal annual installments on January 15, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:11 UTC |
MOLINA ARTURO MDChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · derivative · entry 9 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,971 Underlying: Common Stock · 16,000 shares Expires 2032-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:11 UTC |
MOLINA ARTURO MDChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · derivative · entry 8 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,971 Underlying: Common Stock · 10,000 shares Expires 2032-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:11 UTC |
MOLINA ARTURO MDChief Medical Officer
|
SaleCommon Stock | 16,000 | $44.83 | $717,280.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · nonDerivative · entry 6 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,444 F3 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.50 to $44.99. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:11 UTC |
MOLINA ARTURO MDChief Medical Officer
|
Exercise / conversionCommon Stock | 16,000 | $8.04 | $128,640.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · nonDerivative · entry 5 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:11 UTC |
MOLINA ARTURO MDChief Medical Officer
|
SaleCommon Stock | 10,000 | $44.50 | $445,000.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · nonDerivative · entry 4 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,444 F2 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $43.80 to $44.92. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 27, 2024 Filed Nov 28, 2024 00:11 UTC |
MOLINA ARTURO MDChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $8.04 | $80,400.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · nonDerivative · entry 3 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:08 UTC |
PATEL DINESH V PH DDirector · President and CEO
|
SaleCommon Stock | 21,480 | $46.25 | $993,450.00 |
DisclosureSEC source: 0001104659-24-123806 · tm2429758-1_4seq1.xml · nonDerivative · entry 4 PATEL DINESH V PH D · CIK 0001120477 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 408,455 F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $44.49 to $46.50. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:11 UTC |
MOLINA ARTURO MDChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,529 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · derivative · entry 7 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,971 Underlying: Common Stock · 5,529 shares Expires 2032-11-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option represents a right to purchase a total of 127,500 shares of the Issuer's common stock, one quarter of which vested on November 7, 2023, with the remaining three quarters vesting in equal monthly installments through November 7, 2026, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:11 UTC |
MOLINA ARTURO MDChief Medical Officer
|
SaleCommon Stock | 5,529 | $45.60 | $252,122.40 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · nonDerivative · entry 2 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,444 F1 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.00 to $45.94. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:11 UTC |
MOLINA ARTURO MDChief Medical Officer
|
Exercise / conversionCommon Stock | 5,529 | $8.04 | $44,453.16 |
DisclosureSEC source: 0001104659-24-123809 · tm2429758-3_4seq1.xml · nonDerivative · entry 1 MOLINA ARTURO MD · CIK 0001398940 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:09 UTC |
Gupta SuneelChief Development Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 450 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · derivative · entry 12 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,300 Underlying: Common Stock · 450 shares Expires 2033-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:09 UTC |
Gupta SuneelChief Development Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · derivative · entry 11 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 30,000 shares Expires 2033-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:09 UTC |
Gupta SuneelChief Development Officer
|
Exercise / conversionCommon Stock | 450 | $12.17 | $5,476.50 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · nonDerivative · entry 7 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:09 UTC |
Gupta SuneelChief Development Officer
|
SaleCommon Stock | 19,191 | $45.50 | $873,190.50 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · nonDerivative · entry 6 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,983 F2 · kind: Sale to cover the exercise price of the options. F4 · price: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $45.23 to $45.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 26, 2024 Filed Nov 28, 2024 00:09 UTC |
Gupta SuneelChief Development Officer
|
Exercise / conversionCommon Stock | 30,000 | $12.17 | $365,100.00 |
DisclosureSEC source: 0001104659-24-123807 · tm2429758-2_4seq1.xml · nonDerivative · entry 5 Gupta Suneel · CIK 0001763923 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.